WUGEN Announces Presentations at American Society of Hematology Annual Meeting
Tags:
Oncology
ASH
Company presents first clinically viable therapy to address a cancer with no effective targeted treatment
ST. LOUIS, Nov. 1, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an oral and poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held Dec. 1 - 4 in San Diego. The presentations will provide an analysis of results from a pre-clinical study on WUGEN's innovative gene editing platform for CAR-T cells.
"An off-the-shelf allogeneic CAR-T cell therapy could be the ultimate game changer in the treatment of cancer," said John McKearn, Ph.D., CEO of WUGEN. "Our first priority is addressing unmet medical needs for patients with T cell malignancies, who face a survival rate of only 50% beyond five years. We are paving the way for targeted fratricide-resistant CAR-T cell therapies with our novel technology platform."
Oral Presentation:
Title: Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of UCART and Long-Acting Interleukin-7 Combination TherapyPresenter: Dr. Karl StaserDate/Time: Sunday, Dec. 2, 2018 at 10:15 a.m. PSTLocation: San Diego Convention Center, Room 28DAbstract Number: 340
Poster Presentation:
Title: A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates UCART Proliferation, Differentiation, and Tumor KillingPresenter: Dr. Matthew CooperDate/Time: Saturday, Dec. 1, 2018 at 6:15 p.m. PSTLocation: San Diego Convention Center, Hall GHAbstract Number: 2199
The abstracts were published today on the ASH website at www.hematology.org and are also available on WUGEN's website at www.wugenbio.com.
About WUGEN
WUGEN Inc. is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis. For more information please visit www.wugenbio.com.
For media inquiries contact: David Schull or Travis KruseRusso Partners858-717-2310212-845-4272david.schull@russopartnersllc.com travis.kruse@russopartnersllc.com
SOURCE WUGEN Inc.
http://www.wugenbio.com
More news releases in similar topics
You just read:
News provided by
Nov 01, 2018, 09:00 ET
Share this article
Share this article
